1 3923 85 LIPOPROTEIN LIPASE IN CHRONIC LYMPHOCYTIC LEUKAEMIA - STRONG BIOMARKER WITH LACK OF FUNCTIONAL SIGNIFICANCE. IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL), LIPOPROTEIN LIPASE (LPL) MRNA OVEREXPRESSION IS AN ESTABLISHED POOR PROGNOSTIC MARKER, ITS FUNCTION, HOWEVER, IS POORLY UNDERSTOOD. MEASURING EXTRACELLULAR LPL ENZYMATIC ACTIVITY AND PROTEIN, WE FOUND NO DIFFERENCE BETWEEN LEVELS IN CLL PATIENTS AND THOSE OF CONTROLS, BOTH BEFORE AND AFTER HEPARIN TREATMENT IN VIVO AND IN VITRO. INVESTIGATING LPL KNOCK DOWN EFFECTS, WE DETERMINED FIVE POTENTIAL DOWNSTREAM TARGETS, OF WHICH ONE GENE, STXBP3, REPORTEDLY IS INVOLVED IN FATTY ACID METABOLISM. WHILE POSSIBLY REFLECTING AN EPIGENETIC SWITCH TOWARDS AN INCORRECT TRANSCRIPTIONAL PROGRAM, LPL OVEREXPRESSION BY ITSELF DOES NOT APPEAR TO SIGNIFICANTLY INFLUENCE CLL CELL SURVIVAL. 2013 2 4247 22 METHYLATION STATUS REGULATES LIPOPROTEIN LIPASE EXPRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA. AMONG DIFFERENT PROGNOSTIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), WE PREVIOUSLY DEMONSTRATED THAT LIPOPROTEIN LIPASE (LPL) IS ASSOCIATED WITH AN UNMUTATED IMMUNOGLOBULIN PROFILE AND CLINICAL POOR OUTCOME. DESPITE THE USEFULNESS OF LPL FOR CLL PROGNOSIS, ITS FUNCTIONAL ROLE AND THE MOLECULAR MECHANISM REGULATING ITS EXPRESSION ARE STILL OPEN QUESTIONS. INTERACTION OF CLL B-CELLS WITH THE TISSUE MICROENVIRONMENT FAVORS DISEASE PROGRESSION BY PROMOTING MALIGNANT B-CELL GROWTH. SINCE TISSUE METHYLATION CAN BE ALTERED BY ENVIRONMENTAL FACTORS, WE INVESTIGATED THE METHYLATION STATUS OF THE LPL GENE AND THE POSSIBILITY THAT OVEREXPRESSION COULD BE ASSOCIATED WITH MICROENVIRONMENT SIGNALS. OUR RESULTS SHOW THAT A DEMETHYLATED STATE OF THE LPL GENE IS RESPONSIBLE FOR ITS ANOMALOUS EXPRESSION IN UNMUTATED CLL CASES AND THAT THIS EXPRESSION IS DEPENDENT ON MICROENVIRONMENT SIGNALS. OVERALL, THIS WORK PROPOSES THAT AN EPIGENETIC MECHANISM, TRIGGERED BY THE MICROENVIRONMENT, REGULATES LPL EXPRESSION IN CLL DISEASE. 2013 3 5967 18 TERMINATION OF ACUTE STRESS RESPONSE BY THE ENDOCANNABINOID SYSTEM IS REGULATED THROUGH LYSINE-SPECIFIC DEMETHYLASE 1-MEDIATED TRANSCRIPTIONAL REPRESSION OF 2-AG HYDROLASES ABHD6 AND MAGL. ACUTE ENVIRONMENTAL STRESS RARELY IMPLIES LONG-LASTING NEUROPHYSIOLOGICAL AND BEHAVIORAL ALTERATIONS. ON THE CONTRARY, CHRONIC STRESS EXERTS A POTENT TOXIC EFFECT AT THE GLUTAMATERGIC SYNAPSE WHOSE ALTERED PHYSIOLOGY HAS BEEN RECOGNIZED AS A CORE TRAIT OF NEUROPSYCHIATRIC DISORDERS. THE ENDOCANNABINOID SYSTEM (ECS) PLAYS AN IMPORTANT ROLE IN THE HOMEOSTATIC RESPONSE TO ACUTE STRESS. IN PARTICULAR, STRESS INDUCES SYNTHESIS OF ENDOCANNABINOID (ECB) 2-ARACHIDONYL GLYCEROL (2-AG). 2-AG STIMULATES PRESYNAPTIC CANNABINOID 1 (CB1) RECEPTOR CONTRIBUTING TO STRESS RESPONSE TERMINATION THROUGH INHIBITION OF GLUTAMATE RELEASE, RESTRAINING THEREAFTER ANXIETY AROUSAL. WE EMPLOY MOUSE MODELS OF STRESS RESPONSE COUPLED TO GENE EXPRESSION ANALYSES, UNRAVELLING THAT IN RESPONSE TO ACUTE PSYCHOSOCIAL STRESS IN THE MOUSE HIPPOCAMPUS, ECS-MEDIATED SYNAPTIC MODULATION IS ENHANCED VIA TRANSCRIPTIONAL REPRESSION OF TWO ENZYMES INVOLVED IN 2-AG DEGRADATION: ALPHA/BETA-HYDROLASE DOMAIN CONTAINING 6 (ABHD6) AND MONOACYLGLYCEROL LIPASE (MAGL). SUCH A PROCESS IS ORCHESTRATED BY THE EPIGENETIC COREPRESSOR LSD1 WHO DIRECTLY INTERACTS WITH PROMOTER REGULATORY REGIONS OF ABHD6 AND MAGL. REMARKABLY, NEGATIVE TRANSCRIPTIONAL CONTROL OF ABHD6 AND MAGL IS LOST IN THE HIPPOCAMPUS UPON CHRONIC PSYCHOSOCIAL STRESS, POSSIBLY CONTRIBUTING TO TRAUMA-INDUCED DRIFT OF SYNAPSE PHYSIOLOGY TOWARD UNCONTROLLED GLUTAMATE TRANSMISSION. WE PREVIOUSLY SHOWED THAT IN MICE LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INCREASES ITS HIPPOCAMPAL EXPRESSION IN RESPONSE TO PSYCHOSOCIAL STRESS PREVENTING EXCESSIVE CONSOLIDATION OF ANXIETY-RELATED PLASTICITY. IN THIS WORK, WE UNRAVEL A NODAL EPIGENETIC MODULATION OF ECB TURN OVER, SHEDDING NEW LIGHT ON THE MOLECULAR SUBSTRATE OF CONVERGING STRESS-TERMINATING EFFECTS DISPLAYED BY ECS AND LSD1. 2020 4 350 26 ALTERED DYNAMICS OF LIPID METABOLISM IN MUSCLE CELLS FROM PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY IS AMELIORATED BY 6 MONTHS OF TRAINING. KEY POINTS: REGULAR EXERCISE IMPROVES MUSCLE FUNCTIONAL CAPACITY AND CLINICAL STATE OF PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY (IIM). IN OUR STUDY, WE USED AN IN VITRO MODEL OF HUMAN PRIMARY MUSCLE CELL CULTURES, DERIVED FROM IIM PATIENTS BEFORE AND AFTER A 6-MONTH INTENSIVE SUPERVISED TRAINING INTERVENTION TO ASSESS THE IMPACT OF DISEASE AND EXERCISE ON LIPID METABOLISM DYNAMICS. WE PROVIDE EVIDENCE THAT MUSCLE CELLS FROM IIM PATIENTS DISPLAY ALTERED DYNAMICS OF LIPID METABOLISM AND IMPAIRED ADAPTIVE RESPONSE TO SATURATED FATTY ACID LOAD COMPARED TO HEALTHY CONTROLS. A 6-MONTH INTENSIVE SUPERVISED EXERCISE TRAINING INTERVENTION IN PATIENTS WITH IIM MITIGATED DISEASE EFFECTS IN THEIR CULTURED MUSCLE CELLS, IMPROVING OR NORMALIZING THEIR CAPACITY TO HANDLE LIPIDS. THESE FINDINGS HIGHLIGHT THE PUTATIVE ROLE OF INTRINSIC METABOLIC DEFECTS OF SKELETAL MUSCLE IN THE PATHOGENESIS OF IIM AND THE POSITIVE IMPACT OF EXERCISE, MAINTAINED IN VITRO BY YET UNKNOWN EPIGENETIC MECHANISMS. ABSTRACT: EXERCISE IMPROVES SKELETAL MUSCLE FUNCTION, CLINICAL STATE AND QUALITY OF LIFE IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY (IIM). OUR AIM WAS TO IDENTIFY DISEASE-RELATED METABOLIC PERTURBATIONS AND THE IMPACT OF EXERCISE IN SKELETAL MUSCLE CELLS OF IIM PATIENTS. PATIENTS UNDERWENT A 6-MONTH INTENSIVE SUPERVISED TRAINING INTERVENTION. MUSCLE FUNCTION, ANTHROPOMETRIC AND METABOLIC PARAMETERS WERE EXAMINED AND MUSCLE CELL CULTURES WERE ESTABLISHED (M. VASTUS LATERALIS; BERGSTROM NEEDLE BIOPSY) BEFORE AND AFTER TRAINING FROM PATIENTS AND SEDENTARY AGE/SEX/BODY MASS INDEX-MATCHED CONTROLS. [(14) C]PALMITATE WAS USED TO DETERMINE FAT OXIDATION AND LIPID SYNTHESIS (THIN LAYER CHROMATOGRAPHY). CELLS WERE EXPOSED TO A CHRONIC (3 DAYS) AND ACUTE (3 H) METABOLIC CHALLENGE (THE SATURATED FATTY ACID PALMITATE, 100 MUM). REDUCED OXIDATIVE (INTERMEDIATE METABOLITES, -49%, P = 0.034) AND NON-OXIDATIVE (DIGLYCERIDES, -38%, P = 0.013) LIPID METABOLISM WAS IDENTIFIED IN PALMITATE-TREATED MUSCLE CELLS FROM IIM PATIENTS COMPARED TO CONTROLS. THREE DAYS OF PALMITATE EXPOSURE ELICITED DISTINCT REGULATION OF OXIDATIVE PHOSPHORYLATION (OXPHOS) COMPLEX IV AND COMPLEX V/ATP SYNTHASE (P = 0.012/0.005) AND ADIPOSE TRIGLYCERIDE LIPASE IN PATIENTS COMPARED TO CONTROLS (P = 0.045) (IMMUNOBLOTTING). IMPORTANTLY, 6 MONTHS OF TRAINING IN IIM PATIENTS IMPROVED LIPID METABOLISM (CO(2) , P = 0.010; INTERMEDIATE METABOLITES, P = 0.041) AND ACTIVATION OF AMP KINASE (P = 0.007), AND NEARLY NORMALIZED PALMITATE-INDUCED CHANGES IN OXPHOS PROTEINS IN MYOTUBES FROM IIM PATIENTS, IN PARALLEL WITH IMPROVEMENTS OF PATIENTS' CLINICAL STATE. MYOTUBES FROM IIM PATIENTS DISPLAYED ALTERED DYNAMICS OF LIPID METABOLISM AND IMPAIRED RESPONSE TO METABOLIC CHALLENGE WITH SATURATED FATTY ACID. OUR OBSERVATIONS SUGGEST THAT METABOLIC DEFECTS INTRINSIC TO SKELETAL MUSCLE COULD REPRESENT NON-IMMUNE PATHOMECHANISMS, WHICH CAN CONTRIBUTE TO MUSCLE WEAKNESS IN IIM. A 6-MONTH TRAINING INTERVENTION MITIGATED DISEASE EFFECTS IN MUSCLE CELLS IN VITRO, INDICATING THE EXISTENCE OF EPIGENETIC REGULATORY MECHANISMS. 2021 5 2753 26 EXPRESSION OF BCL2L12 IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: ASSOCIATION WITH CLINICAL AND MOLECULAR PROGNOSTIC MARKERS. DYSREGULATION OF APOPTOSIS IS A DISTINCTIVE FEATURE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), ALTHOUGH A UNIQUE MECHANISM UNDERLYING APOPTOSIS RESISTANCE OF CLL B LYMPHOCYTES HAS NOT BEEN IDENTIFIED YET. ABERRANT EXPRESSION AS WELL AS GENETIC AND EPIGENETIC ALTERATIONS OF NUMEROUS GENES INVOLVED IN DIFFERENT PATHWAYS OF APOPTOSIS REGULATION HAS BEEN DESCRIBED IN CLL. HERE, WE REPORT THE EXPRESSION ANALYSIS OF BCL2L12 (BCL2-LIKE 12), A NOVEL APOPTOTIC GENE BELONGING TO BCL2 FAMILY, IN 58 SERBIAN CLL PATIENTS. QUANTITATIVE REVERSE-TRANSCRIPTASE POLYMERASE CHAIN REACTION (QRT-PCR) ANALYSIS REVEALED A SIGNIFICANT OVEREXPRESSION OF BCL2L12 MRNA IN CLL SAMPLES COMPARED TO NON-LEUKEMIC SAMPLES, IMPLYING ITS ROLE IN THE PATHOGENESIS OF THE DISEASE. RECEIVER OPERATING CHARACTERISTIC (ROC) ANALYSIS SHOWED THAT BCL2L12 EXPRESSION EFFICIENTLY DISCRIMINATES CLL CASES FROM HEALTHY CONTROLS. HOWEVER, RELATIVELY HOMOGENOUS BCL2L12 MRNA EXPRESSION AMONG PATIENTS DID NOT REFLECT THEIR CLINICAL CHARACTERISTICS (WITH THE EXCEPTION OF LACTATE DEHYDROGENASE STATUS AND TIME FROM DIAGNOSIS TO TREATMENT) AND FAILED TO SHOW ASSOCIATION WITH THE MOST INFORMATIVE PROGNOSTIC MARKERS, NAMELY THE MUTATIONAL STATUS OF REARRANGED IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION GENES, CD38 AND LIPOPROTEIN LIPASE GENE (LPL) EXPRESSION. 2013 6 4610 22 NEONATAL DNA METHYLATION AND EARLY-ONSET CONDUCT PROBLEMS: A GENOME-WIDE, PROSPECTIVE STUDY. EARLY-ONSET CONDUCT PROBLEMS (CP) ARE A KEY PREDICTOR OF ADULT CRIMINALITY AND POOR MENTAL HEALTH. WHILE PREVIOUS STUDIES SUGGEST THAT BOTH GENETIC AND ENVIRONMENTAL RISKS PLAY AN IMPORTANT ROLE IN THE DEVELOPMENT OF EARLY-ONSET CP, LITTLE IS KNOWN ABOUT POTENTIAL BIOLOGICAL PROCESSES UNDERLYING THESE ASSOCIATIONS. IN THIS STUDY, WE EXAMINED PROSPECTIVE ASSOCIATIONS BETWEEN DNA METHYLATION (CORD BLOOD AT BIRTH) AND TRAJECTORIES OF CP (4-13 YEARS), USING DATA DRAWN FROM THE AVON LONGITUDINAL STUDY OF PARENTS AND CHILDREN. METHYLOMIC VARIATION AT SEVEN LOCI ACROSS THE GENOME (FALSE DISCOVERY RATE < 0.05) DIFFERENTIATED CHILDREN WHO GO ON TO DEVELOP EARLY-ONSET (N = 174) VERSUS LOW (N = 86) CP, INCLUDING SITES IN THE VICINITY OF THE MONOGLYCERIDE LIPASE (MGLL) GENE (INVOLVED IN ENDOCANNABINOID SIGNALING AND PAIN PERCEPTION). SUBTHRESHOLD ASSOCIATIONS IN THE VICINITY OF THREE CANDIDATE GENES FOR CP (MONOAMINE OXIDASE A [MAOA], BRAIN-DERIVED NEUROTROPHIC FACTOR [BDNF], AND FK506 BINDING PROTEIN 5 [FKBP5]) WERE ALSO IDENTIFIED. WITHIN THE EARLY-ONSET CP GROUP, METHYLATION LEVELS OF THE IDENTIFIED SITES DID NOT DISTINGUISH CHILDREN WHO WILL GO ON TO PERSIST VERSUS DESIST IN CP BEHAVIOR OVER TIME. OVERALL, WE FOUND THAT SEVERAL OF THE IDENTIFIED SITES CORRELATED WITH PRENATAL EXPOSURES, AND NONE WERE LINKED TO KNOWN GENETIC METHYLATION QUANTITATIVE TRAIT LOCI. FINDINGS CONTRIBUTE TO A BETTER UNDERSTANDING OF EPIGENETIC PATTERNS ASSOCIATED WITH EARLY-ONSET CP. 2018 7 5080 13 PHYTOPHARMACOLOGICAL STRATEGIES IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS. TYPE 2 DIABETES MELLITUS (T2DM) IS A CHRONIC DISEASE WHICH CORRESPONDS TO 90% OF THE WORLDWIDE CASES OF DIABETES, MAINLY DUE TO EPIGENETIC FACTORS SUCH AS UNHEALTHY LIFESTYLES. FIRST LINE THERAPEUTIC APPROACHES ARE BASED ON LIFESTYLE CHANGES, MOST OF THE TIME COMPLEMENTED WITH MEDICATION MOSTLY ASSOCIATED WITH SEVERAL SIDE EFFECTS AND HIGH COSTS. AS A RESULT, THE SCIENTIFIC COMMUNITY IS CONSTANTLY WORKING FOR THE DISCOVERY AND DEVELOPMENT OF NATURAL THERAPEUTIC STRATEGIES THAT PROVIDE LOWER FINANCIAL IMPACT AND MINIMIZE SIDE EFFECTS. THIS REVIEW FOCUS ON THESE NATURE-BASED THERAPEUTIC STRATEGIES FOR PREVENTION AND CONTROL OF T2DM, WITH A SPECIAL EMPHASIS ON NATURAL COMPOUNDS THAT PRESENT PHARMACOLOGICAL ACTIVITY AS DIPEPTIDYL PEPTIDASE-4 (DPP4), ALPHA-AMYLASE, ALPHA-GLUCOSIDASE, LIPASE, AND PROTEIN TYROSINE PHOSPHATASE 1B (PTP1B) INHIBITORS. 2020 8 2431 28 EPIGENETIC SILENCING OF MIR-26A1 IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA: IMPACT ON EZH2 EXPRESSION. DOWNREGULATION OF MIR26A1 HAS BEEN REPORTED IN VARIOUS B-CELL MALIGNANCIES; HOWEVER, THE MECHANISM BEHIND ITS DEREGULATION REMAINS LARGELY UNKNOWN. WE INVESTIGATED MIR26A1 METHYLATION AND EXPRESSION LEVELS IN A WELL-CHARACTERIZED SERIES OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MANTLE CELL LYMPHOMA (MCL). FROM 450K METHYLATION ARRAYS, WE FIRST OBSERVED MIR26A1 (CG26054057) AS UNIFORMLY HYPERMETHYLATED IN MCL (N = 24) (ALL >75%), WHILE CLL (N = 18) SHOWED DIFFERENTIAL METHYLATION BETWEEN PROGNOSTIC SUBGROUPS. EXTENDED ANALYSIS USING PYROSEQUENCING CONFIRMED OUR FINDINGS AND REAL-TIME QUANTITATIVE PCR VERIFIED LOW MIR26A1 EXPRESSION IN BOTH CLL (N = 70) AND MCL (N = 38) COMPARED TO NORMAL B-CELLS. NOTABLY, THE LEVEL OF MIR26A1 METHYLATION PREDICTED OUTCOME IN CLL, WITH HIGHER LEVELS SEEN IN POOR-PROGNOSTIC, IGHV-UNMUTATED CLL. SINCE EZH2 WAS RECENTLY REPORTED AS A TARGET FOR MIR26A1, WE ANALYZED THE EXPRESSION LEVELS OF BOTH MIR26A1 AND EZH2 IN PRIMARY CLL SAMPLES AND OBSERVED AN INVERSE CORRELATION. BY OVEREXPRESSION OF MIR26A1 IN CLL AND MCL CELL LINES, REDUCED EZH2 PROTEIN LEVELS WERE OBSERVED USING BOTH WESTERN BLOT AND FLOW CYTOMETRY. IN CONTRAST, METHYL-INHIBITOR TREATMENT LED TO UPREGULATED MIR26A1 EXPRESSION WITH A PARALLEL DECREASE OF EZH2 EXPRESSION. FINALLY, INCREASED LEVELS OF APOPTOSIS WERE OBSERVED IN MIR26A1-OVEREXPRESSING CELL LINES, FURTHER UNDERSCORING THE FUNCTIONAL RELEVANCE OF MIR26A1. IN SUMMARY, WE PROPOSE THAT EPIGENETIC SILENCING OF MIR26A1 IS REQUIRED FOR THE MAINTENANCE OF INCREASED LEVELS OF EZH2, WHICH IN TURN TRANSLATE INTO A WORSE OUTCOME, AS SHOWN IN CLL, HIGHLIGHTING MIR26A1 AS A TUMOR SUPPRESSOR MIRNA. 2016 9 3114 24 GERMLINE ALLELE-SPECIFIC EXPRESSION OF DAPK1 IN CHRONIC LYMPHOCYTIC LEUKEMIA. WE PREVIOUSLY REPORTED A RARE GERMLINE VARIANT (C.1-6531) THAT RESULTED IN ALLELE-SPECIFIC EXPRESSION (ASE) OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) AND PREDISPOSITION TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). WE INVESTIGATED A COHORT OF CLL PATIENTS LACKING THIS MUTATION FOR THE PRESENCE OF ASE OF DAPK1. WE DEVELOPED A NOVEL STRATEGY THAT COMBINES SINGLE-NUCLEOTIDE PRIMER EXTENSION (SNUPE) WITH MALDI-TOF MASS SPECTROMETRY, AND DETECTED GERMLINE DAPK1 ASE IN 17 OUT OF 120 (14.2%) CLL PATIENTS ASSOCIATED WITH A TREND TOWARDS YOUNGER AGE AT DIAGNOSIS. ASE WAS ABSENT IN 63 HEALTHY CONTROLS. GERMLINE CELLS OF CLL PATIENTS WITH ASE SHOWED INCREASED LEVELS OF DNA METHYLATION IN THE PROMOTER REGION, HOWEVER, NEITHER GENETIC NOR FURTHER EPIGENETIC ABERRATIONS COULD BE IDENTIFIED IN THE DAPK1 5' UPSTREAM REGULATORY REGION, WITHIN DISTINCT EXONS OR IN THE 3'-UTR. WE IDENTIFIED B-LYMPHOID MALIGNANCY RELATED CELL LINE MODELS HARBORING ALLELIC IMBALANCE AND FOUND THAT ALLELE-SPECIFIC METHYLATION IN DAPK1 IS ASSOCIATED WITH ASE. OUR DATA INDICATE THAT ASE AT THE DAPK1 GENE LOCUS IS A RECURRENT EVENT, MEDIATED BY EPIGENETIC MECHANISMS AND POTENTIALLY PREDISPOSING TO CLL. 2013 10 5842 25 STRUCTURE OF HUMAN SP140 PHD FINGER: AN ATYPICAL FOLD INTERACTING WITH PIN1. SP140 IS A NUCLEAR LEUKOCYTE-SPECIFIC PROTEIN INVOLVED IN PRIMARY BILIARY CIRRHOSIS AND A RISK FACTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA. THE PRESENCE OF SEVERAL CHROMATIN RELATED MODULES SUCH AS PLANT HOMEODOMAIN (PHD), BROMODOMAIN AND SAND DOMAIN SUGGESTS A ROLE IN CHROMATIN-MEDIATED REGULATION OF GENE EXPRESSION; HOWEVER, ITS REAL FUNCTION IS STILL ELUSIVE. HEREIN WE PRESENT THE SOLUTION STRUCTURE OF SP140-PHD FINGER AND INVESTIGATE ITS ROLE AS EPIGENETIC READER IN VITRO. SP140-PHD PRESENTS AN ATYPICAL PHD FINGER FOLD WHICH DOES NOT BIND TO HISTONE H3 TAILS BUT IS RECOGNIZED BY PEPTIDYLPROLYL ISOMERASE PIN1. PIN1 SPECIFICALLY BINDS TO A PHOSPHOPEPTIDE CORRESPONDING TO THE L3 LOOP OF SP140-PHD AND CATALYZES CIS-TRANS ISOMERIZATION OF A PTHR-PRO BOND. MOREOVER CO-IMMUNOPRECIPITATION EXPERIMENTS DEMONSTRATE FLAG-SP140 INTERACTION WITH ENDOGENOUS PIN1 IN VIVO. OVERALL THESE DATA INCLUDE SP140 IN THE LIST OF THE INCREASING NUMBER OF PIN1 BINDERS AND EXPAND THE REGULATORY POTENTIAL OF PHD FINGERS AS VERSATILE STRUCTURAL PLATFORMS FOR DIVERSIFIED INTERACTIONS. 2014 11 3725 28 INHIBITION OF GLYCOGEN SYNTHASE KINASE-3 ACTIVITY LEADS TO EPIGENETIC SILENCING OF NUCLEAR FACTOR KAPPAB TARGET GENES AND INDUCTION OF APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA B CELLS. CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IS COMMONLY DEFINED AS A DISEASE OF FAILED APOPTOSIS OF B CELLS AND REMAINS AN INCURABLE DISEASE. THE MECHANISM OF RESISTANCE TO APOPTOSIS IN CLL IS COMPLEX AND INFLUENCED BY NUMEROUS FACTORS, INCLUDING NUCLEAR FACTOR KAPPAB (NFKAPPAB)-MEDIATED EXPRESSION OF ANTIAPOPTOTIC MOLECULES. RECENT EVIDENCE INDICATES THAT GLYCOGEN SYNTHASE KINASE-3BETA (GSK-3BETA) POSITIVELY REGULATES NFKAPPAB-MEDIATED GENE TRANSCRIPTION AND CELL SURVIVAL. USING MALIGNANT B CELLS COLLECTED FROM PATIENTS WITH CLL, WE FIND THAT BOTH GSK-3BETA AND NFKAPPAB ACCUMULATE IN THE NUCLEUS OF CLL B CELLS, AND PHARMACOLOGIC INHIBITION OF GSK-3 RESULTS IN DECREASED EXPRESSION OF TWO NFKAPPAB TARGET GENES BCL-2 AND XIAP AND A SUBSEQUENT INCREASE IN CLL B-CELL APOPTOSIS EX VIVO. FURTHERMORE, WE OBSERVED THAT INHIBITION OF GSK-3 LEADS TO A DECREASE IN NFKAPPAB-MEDIATED GENE TRANSCRIPTION BUT DOES NOT AFFECT THE NUCLEAR ACCUMULATION OF NFKAPPAB IN CLL B CELLS. LAST, USING CHROMATIN IMMUNOPRECIPITATION, WE SHOW THAT GSK-3 INHIBITION ABROGATES NFKAPPAB BINDING TO ITS TARGET GENE PROMOTERS (XIAP, BCL-2), IN PART THROUGH EPIGENETIC MODIFICATION OF HISTONES. OUR RESULTS ESTABLISH THAT INHIBITION OF GSK-3 ABROGATES NFKAPPAB BINDING TO ITS TARGET GENE PROMOTERS THROUGH AN EPIGENETIC MECHANISM, ENHANCES APOPTOSIS IN CLL B CELLS EX VIVO AND IDENTIFIES GSK-3 AS A POTENTIAL THERAPEUTIC TARGET IN THE TREATMENT OF CLL. 2007 12 4100 28 MCPH1 MAINTAINS LONG-TERM EPIGENETIC SILENCING OF ANGPT2 IN CHRONIC LYMPHOCYTIC LEUKEMIA. THE MICROCEPHALIN GENE (MCPH1) [ALSO KNOWN AS INHIBITOR OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE (HTERT) EXPRESSION] IS A TUMOR SUPPRESSOR GENE THAT IS FUNCTIONALLY INVOLVED IN THE DNA DAMAGE RESPONSE. ANGIOPOIETIN 2 (ANGPT2) IS A CRUCIAL FACTOR REGULATING TUMOR ANGIOPOIESIS. DEREGULATION OF ANGIOGENESIS IS ONE OF THE HALLMARKS OF MANY CANCERS, INCLUDING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). IN CLL, ANGPT2 IS A WELL-STUDIED POTENTIAL PROGNOSTIC MARKER. AS MCPH1 OVERLAPS WITH THE ANGPT2 TRANSCRIPTION UNIT ON THE SAME CHROMOSOME BUT IN THE OPPOSITE ORIENTATION, WE WANTED TO STUDY THE FUNCTIONAL ROLE OF MCPH1 IN REGULATION OF ANGPT2 IN CLL. THE MRNA EXPRESSION LEVELS OF MCPH1 AND ANGPT2, INCLUDING THE MCPH1 TARGET GENE HTERT, SHOWED SIGNIFICANT DIFFERENCES BETWEEN TWO PROGNOSTIC GROUPS, I.E. IGHV-MUTATED AND IGHV-UNMUTATED (P = 0.007 FOR MCPH1, P = 0.0002 FOR ANGPT2, AND P = 0.00001 FOR HTERT), IN WHICH THE EXPRESSION LEVEL OF MCPH1 WAS INVERSELY CORRELATED WITH THE EXPRESSION LEVELS OF HTERT AND ANGPT2. DOWNREGULATION OF MCPH1 RESULTED IN UPREGULATION OF ANGPT2, ACCOMPANIED BY LOSS OF ITS PROMOTER METHYLATION. USING CHROMATIN IMMUNOPRECIPITATION AND COIMMUNOPRECIPITATION ASSAYS, WE FOUND THAT MCPH1 BINDS TO THE ANGPT2 PROMOTER AND RECRUITS DNA METHYLTRANSFERASES, THEREBY SILENCING ANGPT2. THUS, OUR DATA SUGGEST A NOVEL FUNCTION FOR MCPH1 IN REGULATING AND MAINTAINING ANGPT2 SILENCING IN CLL THROUGH REGULATION OF PROMOTER DNA METHYLATION. 2015 13 3522 22 IL-10 PRODUCTION BY CLL CELLS IS ENHANCED IN THE ANERGIC IGHV MUTATED SUBSET AND ASSOCIATES WITH REDUCED DNA METHYLATION OF THE IL10 LOCUS. CHRONIC LYMPHOCYTIC LEUKEMIAS (CLLS) WITH UNMUTATED (U-CLL) OR MUTATED (M-CLL) IGHV HAVE VARIABLE FEATURES OF IMMUNOSUPPRESSION, POSSIBLY INFLUENCED BY THOSE CLL CELLS ACTIVATED TO PRODUCE INTERLEUKIN 10 (IL-10). THE TWO SUBSETS DIFFER IN THEIR LEVELS OF ANERGY, DEFINED BY LOW SURFACE IMMUNOGLOBULIN M LEVELS/SIGNALING CAPACITY, AND IN THEIR DNA METHYLATION PROFILE, PARTICULARLY VARIABLE IN M-CLL. WE HAVE NOW FOUND THAT LEVELS OF IL-10 PRODUCED BY ACTIVATED CLL CELLS WERE HIGHLY VARIABLE. LEVELS WERE HIGHER IN M-CLL THAN IN U-CLL AND CORRELATED WITH ANERGY. DNA METHYLATION ANALYSIS OF IL10 LOCUS REVEALED TWO PREVIOUSLY UNCHARACTERIZED 'VARIABLY METHYLATED REGIONS' (CLL-VMRS1/2) IN THE GENE BODY, BUT SIMILARLY LOW METHYLATION IN THE PROMOTER OF BOTH U-CLL AND M-CLL. CLL-VMR1/2 METHYLATION WAS LOWER IN M-CLL THAN IN U-CLL AND INVERSELY CORRELATED WITH IL-10 INDUCTION. A FUNCTIONAL SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 3 (STAT3) BINDING SITE IN CLL-VMR2 WAS CONFIRMED BY PROXIMITY LIGATION AND LUCIFERASE ASSAYS, WHEREAS INHIBITION OF SYK-MEDIATED STAT3 ACTIVATION RESULTED IN SUPPRESSION OF IL10. THE DATA SUGGEST EPIGENETIC CONTROL OF IL-10 PRODUCTION. HIGHER TUMOR LOAD MAY COMPENSATE THE REDUCED IL-10 PRODUCTION IN U-CLL, ACCOUNTING FOR CLINICAL IMMUNOSUPPRESSION IN BOTH SUBSETS. THE OBSERVATION THAT SYK INHIBITION ALSO SUPPRESSES IL-10 PROVIDES A POTENTIAL NEW RATIONALE FOR THERAPEUTIC TARGETING AND IMMUNOLOGICAL RESCUE BY SYK INHIBITORS IN CLL. 2017 14 1884 15 ENDOCANNABINOID-EPIGENETIC CROSS-TALK: A BRIDGE TOWARD STRESS COPING. THERE IS NO ARGUMENT WITH REGARD TO THE PHYSICAL AND PSYCHOLOGICAL STRESS-RELATED NATURE OF NEUROPSYCHIATRIC DISORDERS. YET, THE MECHANISMS THAT FACILITATE DISEASE ONSET STARTING FROM MOLECULAR STRESS RESPONSES ARE ELUSIVE. ENVIRONMENTAL STRESS CHALLENGES INDIVIDUALS' EQUILIBRIUM, ENHANCING HOMEOSTATIC REQUEST IN THE ATTEMPT TO STEER DOWN AROUSAL-INSTRUMENTAL MOLECULAR PATHWAYS THAT UNDERLIE HYPERVIGILANCE AND ANXIETY. A RELEVANT HOMEOSTATIC PATHWAY IS THE ENDOCANNABINOID SYSTEM (ECS). IN THIS REVIEW, WE SUMMARIZE RECENT DISCOVERIES UNAMBIGUOUSLY LISTING ECS AS A STRESS COPING MECHANISM. AS STRESS EVOKES HUGE EXCITATORY RESPONSES IN EMOTIONAL-RELEVANT LIMBIC AREAS, THE ECS LIMITS GLUTAMATE RELEASE VIA 2-ARACHYDONILGLYCEROL (2-AG) STRESS-INDUCED SYNTHESIS AND RETROGRADE CANNABINOID 1 (CB1)-RECEPTOR ACTIVATION AT THE SYNAPSE. HOWEVER, ECS SHOWS INTRINSIC VULNERABILITY AS 2-AG OVERSTIMULATION BY CHRONIC STRESS RAPIDLY LEADS TO CB1-RECEPTOR DESENSITIZATION. IN THIS REVIEW, WE EMPHASIZE THE PROTECTIVE ROLE OF 2-AG IN STRESS-RESPONSE TERMINATION AND STRESS RESILIENCY. INTERESTINGLY, WE DISCUSS ECS REGULATION WITH A FURTHER NUCLEAR HOMEOSTATIC SYSTEM WHOSE NATURE IS EXQUISITELY EPIGENETIC, ORCHESTRATED BY LYSINE SPECIFIC DEMETHYLASE 1. WE HERE EMPHASIZE A REMARKABLE EXAMPLE OF STRESS-COPING NETWORK WHERE TRANSCRIPTIONAL HOMEOSTASIS SUBSERVES SYNAPTIC AND BEHAVIORAL ADAPTATION, AIMING AT REDUCING PSYCHIATRIC EFFECTS OF TRAUMATIC EXPERIENCES. 2020 15 15 20 450K-ARRAY ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA CELLS REVEALS GLOBAL DNA METHYLATION TO BE RELATIVELY STABLE OVER TIME AND SIMILAR IN RESTING AND PROLIFERATIVE COMPARTMENTS. IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), THE MICROENVIRONMENT INFLUENCES GENE EXPRESSION PATTERNS; HOWEVER, KNOWLEDGE IS LIMITED REGARDING THE EXTENT TO WHICH METHYLATION CHANGES WITH TIME AND EXPOSURE TO SPECIFIC MICROENVIRONMENTS. USING HIGH-RESOLUTION 450K ARRAYS, WE PROVIDE THE MOST COMPREHENSIVE DNA METHYLATION STUDY OF CLL TO DATE, ANALYZING PAIRED DIAGNOSTIC/FOLLOW-UP SAMPLES FROM IGHV-MUTATED/UNTREATED AND IGHV-UNMUTATED/TREATED PATIENTS (N=36) AND PATIENT-MATCHED PERIPHERAL BLOOD AND LYMPH NODE SAMPLES (N=20). ON AN UNPRECEDENTED SCALE, WE REVEALED 2239 DIFFERENTIALLY METHYLATED CPG SITES BETWEEN IGHV-MUTATED AND UNMUTATED PATIENTS, WITH THE MAJORITY OF SITES POSITIONED OUTSIDE ANNOTATED CPG ISLANDS. INTRIGUINGLY, CLL PROGNOSTIC GENES (FOR EXAMPLE, CLLU1, LPL, ZAP70 AND NOTCH1), EPIGENETIC REGULATOR (FOR EXAMPLE, HDAC9, HDAC4 AND DNMT3B), B-CELL SIGNALING (FOR EXAMPLE, IBTK) AND NUMEROUS TGF-BETA AND NF-KAPPAB/TNF PATHWAY GENES WERE ALTERNATIVELY METHYLATED BETWEEN SUBGROUPS. CONTRARY, DNA METHYLATION OVER TIME WAS DEEMED RATHER STABLE WITH FEW RECURRENT CHANGES NOTED WITHIN SUBGROUPS. ALTHOUGH A LARGER NUMBER OF NON-RECURRENT CHANGES WERE IDENTIFIED AMONG IGHV-UNMUTATED RELATIVE TO MUTATED CASES OVER TIME, THESE EQUATED TO A LOW GLOBAL CHANGE. SIMILARLY, FEW CHANGES WERE IDENTIFIED BETWEEN COMPARTMENT CASES. ALTOGETHER, WE REVEAL CLL SUBGROUPS TO DISPLAY UNIQUE METHYLATION PROFILES AND UNVEIL METHYLATION AS RELATIVELY STABLE OVER TIME AND SIMILAR WITHIN DIFFERENT CLL COMPARTMENTS, IMPLYING ABERRANT METHYLATION AS AN EARLY LEUKEMOGENIC EVENT. 2013 16 2271 22 EPIGENETIC READER SP140 LOSS OF FUNCTION DRIVES CROHN'S DISEASE DUE TO UNCONTROLLED MACROPHAGE TOPOISOMERASES. HOW MIS-REGULATED CHROMATIN DIRECTLY IMPACTS HUMAN IMMUNE DISORDERS IS POORLY UNDERSTOOD. SPECKLED PROTEIN 140 (SP140) IS AN IMMUNE-RESTRICTED PHD AND BROMODOMAIN-CONTAINING EPIGENETIC "READER," AND SP140 LOSS-OF-FUNCTION MUTATIONS ASSOCIATE WITH CROHN'S DISEASE (CD), MULTIPLE SCLEROSIS (MS), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). HOWEVER, THE RELEVANCE OF THESE MUTATIONS AND MECHANISMS UNDERLYING SP140-DRIVEN PATHOGENICITY REMAINS UNEXPLORED. USING A GLOBAL PROTEOMIC STRATEGY, WE IDENTIFIED SP140 AS A REPRESSOR OF TOPOISOMERASES (TOPS) THAT MAINTAINS HETEROCHROMATIN AND MACROPHAGE FATE. IN HUMANS AND MICE, SP140 LOSS RESULTED IN UNLEASHED TOP ACTIVITY, DE-REPRESSION OF DEVELOPMENTALLY SILENCED GENES, AND ULTIMATELY DEFECTIVE MICROBE-INDUCIBLE MACROPHAGE TRANSCRIPTIONAL PROGRAMS AND BACTERIAL KILLING THAT DRIVE INTESTINAL PATHOLOGY. PHARMACOLOGICAL INHIBITION OF TOP1/2 RESCUED THESE DEFECTS. FURTHERMORE, EXACERBATED COLITIS WAS RESTORED WITH TOP1/2 INHIBITORS IN SP140(-/-) MICE, BUT NOT WILD-TYPE MICE, IN VIVO. COLLECTIVELY, WE IDENTIFY SP140 AS A TOP REPRESSOR AND REVEAL REPURPOSING OF TOP INHIBITION TO REVERSE IMMUNE DISEASES DRIVEN BY SP140 LOSS. 2022 17 4023 22 LSD1-S112A EXACERBATES THE PATHOGENESIS OF CSE/LPS-INDUCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN MICE. LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) IS AN EPIGENETIC REGULATOR THAT MODULATES THE CHROMATIN STATUS, CONTRIBUTING TO GENE ACTIVATION OR REPRESSION. THE POST-TRANSLATIONAL MODIFICATION OF LSD1 IS CRITICAL FOR THE REGULATION OF MANY OF ITS BIOLOGICAL PROCESSES. PHOSPHORYLATION OF SERINE 112 OF LSD1 BY PROTEIN KINASE C ALPHA (PKCALPHA) IS CRUCIAL FOR REGULATING INFLAMMATION, BUT ITS PHYSIOLOGICAL SIGNIFICANCE IS NOT FULLY UNDERSTOOD. THIS STUDY AIMED TO INVESTIGATE THE ROLE OF LSD1-S112A, A PHOSPHORYLATION DEFECTIVE MUTANT, IN THE CIGARETTE SMOKE EXTRACT/LPS-INDUCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MODEL USING LSD1SA/SA MICE AND TO EXPLORE THE POTENTIAL MECHANISM UNDERPINNING THE DEVELOPMENT OF COPD. WE FOUND THAT LSD1SA/SA MICE EXHIBITED INCREASED SUSCEPTIBILITY TO CSE/LPS-INDUCED COPD, INCLUDING HIGH INFLAMMATORY CELL INFLUX INTO THE BRONCHOALVEOLAR LAVAGE FLUID AND AIRSPACE ENLARGEMENT. ADDITIONALLY, THE HIGH GENE EXPRESSION ASSOCIATED WITH THE INFLAMMATORY RESPONSE AND OXIDATIVE STRESS WAS OBSERVED IN CELLS AND MICE CONTAINING LSD1-S112A. SIMILAR RESULTS WERE OBTAINED FROM THE MOUSE EMBRYONIC FIBROBLASTS EXPOSED TO A PKCALPHA INHIBITOR, GO6976. THUS, THE LACK OF LSD1 PHOSPHORYLATION EXACERBATES CSE/LPS-INDUCED COPD BY ELEVATING INFLAMMATION AND OXIDATIVE STRESS. [BMB REPORTS 2021; 54(10): 522-527]. 2021 18 5871 22 SUSTAINED NF-KAPPAB ACTIVITY IN CHRONIC LYMPHOCYTIC LEUKEMIA IS INDEPENDENT OF GENETIC AND EPIGENETIC ALTERATIONS IN THE TNFAIP3 (A20) LOCUS. INAPPROPRIATE NUCLEAR FACTOR (NF) KAPPAB ACTIVITY IS ONE MAJOR HALLMARK OF B-CELL MALIGNANCIES AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). NFKAPPAB-DEPENDENT GENES ARE INVOLVED IN ANTIAPOPTOSIS, CELL PROLIFERATION AND METASTASIS AND ARE RESPONSIBLE FOR SURVIVAL AND PROLIFERATION OF TUMORS. HOWEVER, THE MECHANISMS OF NFKAPPAB ACTIVITY IN CLL STILL NEED TO BE ELUCIDATED. PREVIOUSLY, WE IDENTIFIED TRANSLOCATIONS IN A REGION ON CHROMOSOME 6Q THAT ENCODES TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3, WHICH IS A KEY PLAYER IN NEGATIVE FEEDBACK LOOP REGULATION OF NFKAPPAB. INACTIVATION OF THIS UBIQUITIN-EDITING ENZYME IS INVOLVED IN IMMUNOPATHOLOGIES AND IN TUMORIGENESIS. FREQUENT MUTATIONS IN THE A20 LOCUS--LEADING TO SUSTAINED NFKAPPAB ACTIVITY--COULD BE SHOWN TO PLAY A DOMINANT ROLE IN DEVELOPMENT OF DIFFERENT B-CELL MALIGNANCIES. TO CHECK IF A20 IS INVOLVED IN UPREGULATION OF NFKAPPAB ACTIVITY IN CLL, WE SEQUENCED EXONS 2-9 OF THE A20 GENE IN 55 CLL DNA SAMPLES. FURTHERMORE, WE DETERMINED THE METHYLATION STATUS OF THE PROMOTER REGION IN 63 CLL DNA SAMPLES AND COMPARED TO 10 CONTROL DNAS OF B CELLS FROM HEALTHY DONORS. CONTRARY TO REPORTS FROM OTHER B-CELL MALIGNANCIES, THE A20 REGION SHOWED NEITHER MUTATIONS NOR ABERRANT DNA METHYLATION. MOREOVER, ITS EXPRESSION COULD BE CONFIRMED BY IMMUNOBLOTTING AND SHOWING COMPARABLE RESULTS TO HEALTHY B CELLS. THESE RESULTS INDICATE THAT MALIGNANT DEVELOPMENT IN CLL DIFFERS FROM MOST OF OTHER B-CELL MALIGNANCIES, WHICH SHOW FREQUENT INACTIVATION OF A20. 2011 19 5915 25 TARGETING A PHOSPHO-STAT3-MIRNAS PATHWAY IMPROVES VESICULAR HEPATIC STEATOSIS IN AN IN VITRO AND IN VIVO MODEL. NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) IS A LEADING CAUSE OF CHRONIC LIVER DISEASE. ALTHOUGH GENETIC PREDISPOSITION AND EPIGENETIC FACTORS CONTRIBUTE TO THE DEVELOPMENT OF NAFLD, OUR UNDERSTANDING OF THE MOLECULAR MECHANISM INVOLVED IN THE PATHOGENESIS OF THE DISEASE IS STILL EMERGING. HERE WE INVESTIGATED A POSSIBLE ROLE OF A MICRORNAS-STAT3 PATHWAY IN THE INDUCTION OF HEPATIC STEATOSIS. DIFFERENTIATED HEPARG CELLS TREATED WITH THE FATTY ACID SODIUM OLEATE (FATTY DHEPARG) RECAPITULATED FEATURES OF LIVER VESICULAR STEATOSIS AND ACTIVATED A CELL-AUTONOMOUS INFLAMMATORY RESPONSE, INDUCING STAT3-TYROSINE-PHOSPHORYLATION. WITH A GENOME-WIDE APPROACH (CHROMATIN IMMUNOPRECIPITATION SEQUENCING), MANY PHOSPHO-STAT3 BINDING SITES WERE IDENTIFIED IN FATTY DHEPARG CELLS AND SEVERAL STAT3 AND/OR NAFLD-REGULATED MICRORNAS SHOWED INCREASED EXPRESSION LEVELS, INCLUDING MIR-21. INNOVATIVE CARS (COHERENT ANTI-STOKES RAMAN SCATTERING) MICROSCOPY REVEALED THAT CHEMICAL INHIBITION OF STAT3 ACTIVITY DECREASED LIPID ACCUMULATION AND DEREGULATED STAT3-RESPONSIVE MICRORNAS, INCLUDING MIR-21, IN LIPID OVERLOADED DHEPARG CELLS. WE WERE ABLE TO SHOW IN VIVO THAT REDUCING PHOSPHO-STAT3-MIR-21 LEVELS IN C57/BL6 MICE LIVER, BY LONG-TERM TREATMENT WITH METFORMIN, PROTECTED MICE FROM AGING-DEPENDENT HEPATIC VESICULAR STEATOSIS. OUR RESULTS IDENTIFIED A MICRORNAS-PHOSPHOSTAT3 PATHWAY INVOLVED IN THE DEVELOPMENT OF HEPATIC STEATOSIS, WHICH MAY REPRESENT A MOLECULAR MARKER FOR BOTH DIAGNOSIS AND THERAPEUTIC TARGETING. 2018 20 1662 17 DOWNREGULATION OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) IN CHRONIC LYMPHOCYTIC LEUKEMIA. THE HERITABILITY OF B CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IS RELATIVELY HIGH; HOWEVER, NO PREDISPOSING MUTATION HAS BEEN CONVINCINGLY IDENTIFIED. WE SHOW THAT LOSS OR REDUCED EXPRESSION OF DEATH-ASSOCIATED PROTEIN KINASE 1 (DAPK1) UNDERLIES CASES OF HERITABLE PREDISPOSITION TO CLL AND THE MAJORITY OF SPORADIC CLL. EPIGENETIC SILENCING OF DAPK1 BY PROMOTER METHYLATION OCCURS IN ALMOST ALL SPORADIC CLL CASES. FURTHERMORE, WE DEFINED A DISEASE HAPLOTYPE, WHICH SEGREGATES WITH THE CLL PHENOTYPE IN A LARGE FAMILY. DAPK1 EXPRESSION OF THE CLL ALLELE IS DOWNREGULATED BY 75% IN GERMLINE CELLS DUE TO INCREASED HOXB7 BINDING. IN THE BLOOD CELLS FROM AFFECTED FAMILY MEMBERS, PROMOTER METHYLATION RESULTS IN ADDITIONAL LOSS OF DAPK1 EXPRESSION. THUS, REDUCED EXPRESSION OF DAPK1 CAN RESULT FROM GERMLINE PREDISPOSITION, AS WELL AS EPIGENETIC OR SOMATIC EVENTS CAUSING OR CONTRIBUTING TO THE CLL PHENOTYPE. 2007